menu
    • menu

    Company profile for Klocke Pharma Service GmbH

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The Klocke Group companies are primarily specialising in contract manufacturing and contract packaging of drug products, vaccines and cosmetic products. The traditionally family owned group employs more than 1.500 people. On six sites in Europe and in the USA, the group offers a broad range of services for manufacturing and packaging of pharmaceutical products. The KLOCKE sites in Appenweier, Dessau, Stade and Weingarten offer...
    The Klocke Group companies are primarily specialising in contract manufacturing and contract packaging of drug products, vaccines and cosmetic products. The traditionally family owned group employs more than 1.500 people. On six sites in Europe and in the USA, the group offers a broad range of services for manufacturing and packaging of pharmaceutical products. The KLOCKE sites in Appenweier, Dessau, Stade and Weingarten offer a broad range of services specialising in contract manufacturing and contract packaging of pharmaceutical and medicinal poducts. This includes manufacture of both solid and liquid forms, packaging of most pharmaceutical product forms, and many accompanying services.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Klocke Pharma Service GmbHGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Strassburger Str. 77 D-77767 Appenweier-Urloffen
    Telephone
    Telephone
    +49 (7805) 401 0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.klocke.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

    Details:

    VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.


    Lead Product(s): VLA2001,Aluminium Hydroxide,CPG ODN 1018

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Valneva

    Deal Size: $39.9 million Upfront Cash: $35.5 million

    Deal Type: Termination September 16, 2022

    blank

    01

    IDT Biologika GmbH

    Germany
    arrow
    VMX
    Not Confirmed

    IDT Biologika GmbH

    Germany
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VLA2001,Aluminium Hydroxide,CPG ODN 1018

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Valneva

    Deal Size : $39.9 million

    Deal Type : Termination

    DEALS_DEV arrow-down

    Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

    Details : VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging technology. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : $35.5 million

    September 16, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    COVID-19 Vaccine Developed by German Research Group Fails in Early Trial

    Details:

    A coronavirus vaccine, MVA-SARS-2-S vaccine, developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans.


    Lead Product(s): MVA-SARS-2-S Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Vaccine

    Recipient: German Center for Infection Research

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 08, 2021

    blank

    02

    IDT Biologika GmbH

    Germany
    arrow
    VMX
    Not Confirmed

    IDT Biologika GmbH

    Germany
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MVA-SARS-2-S Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Recipient : German Center for Infection Research

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    COVID-19 Vaccine Developed by German Research Group Fails in Early Trial

    Details : A coronavirus vaccine, MVA-SARS-2-S vaccine, developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    January 08, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Germany Approves Third Trial of COVID-19 Vaccine Candidate

    Details:

    The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.


    Lead Product(s): MVA-SARS-2-S Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Vaccine

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 02, 2020

    blank

    03

    IDT Biologika GmbH

    Germany
    arrow
    VMX
    Not Confirmed

    IDT Biologika GmbH

    Germany
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MVA-SARS-2-S Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Germany Approves Third Trial of COVID-19 Vaccine Candidate

    Details : The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    October 02, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search